FDA approves new treatment for adults with relapsed or refractory acute lymphoblastic leukemia - FDA Press Releases

The U.S. Food and Drug Administration today approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

from Food and Drug Administration--Press Releases http://ift.tt/2vMdJjA
via IFTTT